Guangzhou Sinogen Pharmaceutical Co.，Ltd. has developed an innovative oncolytic drug, SGN1. As far as we know, SGN1 represents the first biological bacterial-based oncolytic technology for malignant tumors. We have filed multiple global intellectual protections about SGN1 covering wide indications of different malignant solid tumors. At present, we have completed preliminary research and development, pre-clinical efficacy evaluation, safety toxicology evaluation, production process formulation, product quality control standards and clinical research. After gaining IRB-approval from several hospitals, we carried out some clinical studies in patients with advanced late stage lung cancer, squamous cell lung cancer, hepatic cancer, and sarcoma. SGN1 proved to safe and effective in the control and reduction of tumors after local and/or intravenous administration.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):